Eden Bioscience: Xiamen Yixiang intends to reduce its holding of the company's shares by no more than 3.00%

Adherbiotech announced that Xiamen Yixiang Investment Partnership Enterprise, a shareholder holding more than 5% of the Company's shares, plans to reduce its holdings of the Company's shares through block trading and concentrated bidding within three months after the announcement date after fifteen consecutive trading days, with a reduction of no more than 11.7918 million shares, accounting for 3.00% of the Company's total share capital.